Lantern Pharma Launches withZeta.ai Platform to Accelerate Rare Cancer Drug Discovery

Lantern Pharma Inc. has announced the commercial launch of withZeta.ai, its multi-agentic AI co-scientist platform designed specifically for rare cancer drug discovery. The platform, built from the company’s proprietary RADR oncology-focused AI technologies, is now available through subscription models across academic and commercial tiers, establishing what the company describes as a new non-dilutive revenue stream.

The launch represents a strategic expansion for Lantern Pharma beyond its clinical-stage pipeline, positioning the company to generate revenue from research institutions and pharmaceutical companies seeking to accelerate their oncology programs. The platform will be showcased at a private investor event at Nasdaq MarketSite in New York on April 16, 2026, followed by public demonstrations at the American Association for Cancer Research Annual Meeting in San Diego from April 17–22.

According to company descriptions, withZeta.ai functions as an autonomous AI co-scientist that investigates, reasons, and synthesizes scientific evidence across the full spectrum of rare cancer research. The platform is designed to accelerate molecular design, clinical development, and biomedical research specifically for rare cancers, addressing what the company identifies as the unique biology, economics, and urgency of this research area.

Lantern Pharma operates an AI Center of Excellence in Bengaluru, India, and is headquartered in Dallas, Texas. The company’s clinical pipeline includes several oncology candidates, including LP-184, LP-284, and LP-300, which is being evaluated in the HARMONIC Phase 2 trial for never-smoker patients with relapsed advanced lung adenocarcinoma. LP-184 is also being developed for pediatric CNS cancers through Starlight Therapeutics, Lantern’s wholly owned CNS-focused subsidiary.

The commercial availability of withZeta.ai marks a significant milestone in the convergence of artificial intelligence and oncology research. Researchers interested in the platform can learn more and subscribe at withzeta.ai. Additional information about Lantern Pharma is available through the company’s newsroom at https://ibn.fm/LTRN.

This development comes as artificial intelligence continues to transform biomedical research, with platforms like withZeta.ai representing the next generation of tools designed to accelerate drug discovery timelines and potentially bring treatments to patients more rapidly. The subscription model allows researchers worldwide to access sophisticated AI capabilities without the need for extensive in-house infrastructure, potentially democratizing access to advanced computational tools for rare cancer research.

This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is Lantern Pharma Launches withZeta.ai Platform to Accelerate Rare Cancer Drug Discovery.

The post Lantern Pharma Launches withZeta.ai Platform to Accelerate Rare Cancer Drug Discovery appeared first on citybuzz.